A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
Study Identifier
M10-459
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
18 - 65 Years
Protocol Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Study Locations
Location
Status
Location
Site Reference ID/Investigator# 17665
Anaheim, California, United States, 92801
Status
Not applicable
Location
Site Reference ID/Investigator# 17367
Los Angeles, California, United States, 90036
Status
Not applicable
Location
Site Reference ID/Investigator# 17672
Los Angeles, California, United States, 90048
Status
Not applicable
Location
Site Reference ID/Investigator# 10381
Orlando, Florida, United States, 32803
Status
Not applicable
Location
Site Reference ID/Investigator# 17667
Baton Rouge, Louisiana, United States, 70808
Status
Not applicable
Location
Site Reference ID/Investigator# 14461
San Antonio, Texas, United States, 78215
Status
Not applicable
Showing {first} - {last} of {total} Results